外科理论与实践

外科理论与实践 >

2022 , Vol. 27 >Issue 02: 119 - 122

DOI: https://doi.org/10.16139/j.1007-9610.2022.02.006

专家论坛

肝癌肝移植全过程管理及治疗进展

展开
  • 1.上海交通大学医学院附属仁济医院肝脏外科,上海 200127
    2.上海市器官移植研究所,上海 200127
    3.上海市器官移植与免疫工程技术研究中心,上海 200127

收稿日期: 2022-01-25

  网络出版日期: 2022-06-16

基金资助

上海市申康中心临床科技创新项目“普外科专科联盟”;国家自然科学基金(81972205);国家自然科学基金重大研究计划(92059205);上海申康医院发展中心三年行动计划关键支撑项目(SHDC2020CR5012)

收起

Liver transplantation in treatment of hepatocellular carcinoma: management of whole⁃process and progress in treatment

Expand

Received date: 2022-01-25

  Online published: 2022-06-16

Fold

本文引用格式

冯浩, 吕子成, 夏强 . 肝癌肝移植全过程管理及治疗进展[J]. 外科理论与实践, 2022 , 27(02) : 119 -122 . DOI: 10.16139/j.1007-9610.2022.02.006

参考文献

[1] Kardashian A, Florman SS, Haydel B, et al. Liver transplantation outcomes in a U.S. multicenter cohort of 789 patients with hepatocellular carcinoma presenting beyond milan criteria[J]. Hepatology, 2020, 72(6):2014-2028.
[2] Ziogas IA, Giannis D, Economopoulos KP, et al. Liver transplantation for intrahepatic cholangiocarcinoma: a meta-analysis and meta-regression of survival rates[J]. Transplantation, 2021, 105(10):2263-2271.
[3] Giannis D, Sideris G, Kakos CD, et al. The role of liver transplantation for colorectal liver metastases: a systema-tic review and pooled analysis[J]. Transplant Rev (Orlando), 2020, 34(4):100570.
[4] Moris D, Tsilimigras DI, Ntanasis-Stathopoulos I, et al. Liver transplantation in patients with liver metastases from neuroendocrine tumors: a systematic review[J]. Surgery, 2017, 162(3):525-536.
[5] Sapisochin G, Hibi T, Toso C, et al. Transplant oncology in primary and metastatic liver tumor: principles, evidence and opportunities[J]. Ann Surg, 2021, 73(3):483-493.
[6] 冯浩, 夏强. 肝移植与肿瘤:发展、机遇与挑战[J]. 中华器官移植杂志, 2021, 42(2):65-67.
[7] Benson AB, D′Angelica MI, Abbott DE, et al. Hepatobi-liary cancers, version 2. 2021, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021, 19(5):541-565.
[8] Jia AY, Popovic A, Mohan AA, et al. Development, practice patterns, and early clinical outcomes of a multidisciplinary liver cancer clinic[J]. Cancer Control, 2021, 28:10732748211009945.
[9] 张子杰, 乔子耘, 冯浩, 等. 系统治疗在肝癌术前新辅助治疗中应用进展[J]. 中国实用外科杂志, 2021, 41(3):326-331.
[10] Kardashian A, Florman SS, Haydel B, et al. Liver transplantation outcomes in a US multicenter cohort of 789 patients with hepatocellular carcinoma presenting beyond Milan criteria[J]. Hepatology, 2020, 72(6):2014-2028.
[11] Cambridge WA, Fairfield C, Powell JJ, et al. Meta-analysis and meta-regression of survival after liver transplantation for unresectable perihilar cholangiocarcinoma[J]. Ann Surg, 2021, 273(2):240-250.
[12] Potter W, Davidi S, Jacobovitch S, et al. Tumor treating fields (TTFields) in combination with sorafenib inhibit hepatocellular carcinoma in vitro and in vivo[J]. J Clin Oncol, 2022, 40(4 suppl):464-464.
[13] Zhang YF, Guo RP, Zou RH, et al. Efficacy and safety of preoperative chemoembolization for resectable hepatocellular carcinoma with portal vein invasion: a prospective comparative study[J]. Eur Radiol, 2016, 26(7):2078-2088.
[14] Xu J, Shen ZY, Chen XG, et al. A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation[J]. Hepatology, 2007, 45(2):269-276.
[15] Han B, Ding H, Zhao S, et al. Potential role of adjuvant lenvatinib in improving disease-free survival for patients with high-risk hepatitis B virus-related hepatocellular carcinoma following liver transplantation: a retrospective, case control study[J]. Front Oncol, 2020, 10:562103.
[16] Chen YY, Chen CL, Lin CC, et al. Efficacy and safety of lenvatinib in hepatocellular carcinoma patients with liver transplantation: a case-control study[J]. Cancers (Basel), 2021, 13(18):4584.
[17] European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1):182-236.
[18] Zhou B, Shan H, Zhu KS, et al. Chemoembolization with lobaplatin mixed with iodized oil for unresectable recurrent hepatocellular carcinoma after orthotopic liver transplantation[J]. J Vasc Interv Radiol, 2010, 21(3):333-338.
[19] Ko HK, Ko GY, Yoon HK, et al. Tumor response to transcatheter arterial chemoembolization in recurrent hepatocellular carcinoma after living donor liver transplantation[J]. Korean J Radiol, 2007, 8(4):320-327.
[20] Au KP, Chiang CL, Chan ACY, et al. Initial experience with stereotactic body radiotherapy for intrahepatic hepatocellular carcinoma recurrence after liver transplantation[J]. World J Clin Cases, 2020, 8(13):2758-2768.
[21] Walburn T, Moon AM, Hayashi PH, et al. Stereotactic body radiation therapy for recurrent, isolated hepatocellular carcinoma lymph node metastasis with or without prior liver transplantation[J]. Cureus, 2020, 12(8):e9988.
Options
文章导航

/

〈 〉